
Global CGRP Monoclonal Antibodies Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global CGRP Monoclonal Antibodies market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for CGRP Monoclonal Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for CGRP Monoclonal Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for CGRP Monoclonal Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of CGRP Monoclonal Antibodies include Alder Therapeutics, Amgen Inc., Daiichi Sankyo Co., Ltd., Pfizer Inc., Lilly Inc., Lundbeck, Novartis International AG and Teva, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CGRP Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CGRP Monoclonal Antibodies.
The CGRP Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CGRP Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
CGRP Monoclonal Antibodies Segment by Company
Alder Therapeutics
Amgen Inc.
Daiichi Sankyo Co., Ltd.
Pfizer Inc.
Lilly Inc.
Lundbeck
Novartis International AG
Teva
CGRP Monoclonal Antibodies Segment by Type
Erenumab
Fremanezumab
Galcanezumab
Eptinezumab
CGRP Monoclonal Antibodies Segment by Application
Specialty Clinic
Hospital
Others
CGRP Monoclonal Antibodies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGRP Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CGRP Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGRP Monoclonal Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of CGRP Monoclonal Antibodies companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global CGRP Monoclonal Antibodies market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for CGRP Monoclonal Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for CGRP Monoclonal Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for CGRP Monoclonal Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of CGRP Monoclonal Antibodies include Alder Therapeutics, Amgen Inc., Daiichi Sankyo Co., Ltd., Pfizer Inc., Lilly Inc., Lundbeck, Novartis International AG and Teva, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CGRP Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CGRP Monoclonal Antibodies.
The CGRP Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CGRP Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
CGRP Monoclonal Antibodies Segment by Company
Alder Therapeutics
Amgen Inc.
Daiichi Sankyo Co., Ltd.
Pfizer Inc.
Lilly Inc.
Lundbeck
Novartis International AG
Teva
CGRP Monoclonal Antibodies Segment by Type
Erenumab
Fremanezumab
Galcanezumab
Eptinezumab
CGRP Monoclonal Antibodies Segment by Application
Specialty Clinic
Hospital
Others
CGRP Monoclonal Antibodies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGRP Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CGRP Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGRP Monoclonal Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of CGRP Monoclonal Antibodies companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
89 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global CGRP Monoclonal Antibodies Market Size Overview by Region 2020 VS 2024 VS 2031
- 1.4 Global CGRP Monoclonal Antibodies Market Size by Region (2020-2031)
- 1.4.1 Global CGRP Monoclonal Antibodies Market Size by Region (2020-2025)
- 1.4.2 Global CGRP Monoclonal Antibodies Market Size by Region (2026-2031)
- 1.5 Key Regions CGRP Monoclonal Antibodies Market Size (2020-2031)
- 1.5.1 North America CGRP Monoclonal Antibodies Market Size Growth Rate (2020-2031)
- 1.5.2 Europe CGRP Monoclonal Antibodies Market Size Growth Rate (2020-2031)
- 1.5.3 Asia-Pacific CGRP Monoclonal Antibodies Market Size Growth Rate (2020-2031)
- 1.5.4 South America CGRP Monoclonal Antibodies Market Size Growth Rate (2020-2031)
- 1.5.5 Middle East & Africa CGRP Monoclonal Antibodies Market Size Growth Rate (2020-2031)
- 2 CGRP Monoclonal Antibodies Market by Type
- 2.1 Type Introduction
- 2.1.1 Erenumab
- 2.1.2 Fremanezumab
- 2.1.3 Galcanezumab
- 2.1.4 Eptinezumab
- 2.2 Global CGRP Monoclonal Antibodies Market Size by Type
- 2.2.1 Global CGRP Monoclonal Antibodies Market Size Overview by Type (2020-2031)
- 2.2.2 Global CGRP Monoclonal Antibodies Historic Market Size Review by Type (2020-2025)
- 2.2.3 Global CGRP Monoclonal Antibodies Market Size Forecasted by Type (2026-2031)
- 2.3 Global CGRP Monoclonal Antibodies Market Size by Regions
- 2.3.1 North America CGRP Monoclonal Antibodies Market Size Breakdown by Type (2020-2025)
- 2.3.2 Europe CGRP Monoclonal Antibodies Market Size Breakdown by Type (2020-2025)
- 2.3.3 Asia-Pacific CGRP Monoclonal Antibodies Market Size Breakdown by Type (2020-2025)
- 2.3.4 South America CGRP Monoclonal Antibodies Market Size Breakdown by Type (2020-2025)
- 2.3.5 Middle East and Africa CGRP Monoclonal Antibodies Market Size Breakdown by Type (2020-2025)
- 3 CGRP Monoclonal Antibodies Market by Application
- 3.1 Type Introduction
- 3.1.1 Specialty Clinic
- 3.1.2 Hospital
- 3.1.3 Others
- 3.2 Global CGRP Monoclonal Antibodies Market Size by Application
- 3.2.1 Global CGRP Monoclonal Antibodies Market Size Overview by Application (2020-2031)
- 3.2.2 Global CGRP Monoclonal Antibodies Historic Market Size Review by Application (2020-2025)
- 3.2.3 Global CGRP Monoclonal Antibodies Market Size Forecasted by Application (2026-2031)
- 3.3 Global CGRP Monoclonal Antibodies Market Size by Regions
- 3.3.1 North America CGRP Monoclonal Antibodies Market Size Breakdown by Application (2020-2025)
- 3.3.2 Europe CGRP Monoclonal Antibodies Market Size Breakdown by Application (2020-2025)
- 3.3.3 Asia-Pacific CGRP Monoclonal Antibodies Market Size Breakdown by Application (2020-2025)
- 3.3.4 South America CGRP Monoclonal Antibodies Market Size Breakdown by Application (2020-2025)
- 3.3.5 Middle East and Africa CGRP Monoclonal Antibodies Market Size Breakdown by Application (2020-2025)
- 4 Global Market Dynamics
- 4.1 CGRP Monoclonal Antibodies Industry Trends
- 4.2 CGRP Monoclonal Antibodies Industry Drivers
- 4.3 CGRP Monoclonal Antibodies Industry Opportunities and Challenges
- 4.4 CGRP Monoclonal Antibodies Industry Restraints
- 5 Competitive Insights by Company
- 5.1 Global Top Players by CGRP Monoclonal Antibodies Revenue (2020-2025)
- 5.2 Global CGRP Monoclonal Antibodies Industry Company Ranking, 2023 VS 2024 VS 2025
- 5.3 Global CGRP Monoclonal Antibodies Key Company Headquarters & Area Served
- 5.4 Global CGRP Monoclonal Antibodies Company, Product Type & Application
- 5.5 Global CGRP Monoclonal Antibodies Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global CGRP Monoclonal Antibodies Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 CGRP Monoclonal Antibodies Players Market Share by Revenue in 2024
- 5.6.3 2024 CGRP Monoclonal Antibodies Tier 1, Tier 2, and Tier 3
- 6 Company Profiles
- 6.1 Alder Therapeutics
- 6.1.1 Alder Therapeutics Comapny Information
- 6.1.2 Alder Therapeutics Business Overview
- 6.1.3 Alder Therapeutics CGRP Monoclonal Antibodies Revenue, Global Share and Gross Margin (2020-2025)
- 6.1.4 Alder Therapeutics CGRP Monoclonal Antibodies Product Portfolio
- 6.1.5 Alder Therapeutics Recent Developments
- 6.2 Amgen Inc.
- 6.2.1 Amgen Inc. Comapny Information
- 6.2.2 Amgen Inc. Business Overview
- 6.2.3 Amgen Inc. CGRP Monoclonal Antibodies Revenue, Global Share and Gross Margin (2020-2025)
- 6.2.4 Amgen Inc. CGRP Monoclonal Antibodies Product Portfolio
- 6.2.5 Amgen Inc. Recent Developments
- 6.3 Daiichi Sankyo Co., Ltd.
- 6.3.1 Daiichi Sankyo Co., Ltd. Comapny Information
- 6.3.2 Daiichi Sankyo Co., Ltd. Business Overview
- 6.3.3 Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Revenue, Global Share and Gross Margin (2020-2025)
- 6.3.4 Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Product Portfolio
- 6.3.5 Daiichi Sankyo Co., Ltd. Recent Developments
- 6.4 Pfizer Inc.
- 6.4.1 Pfizer Inc. Comapny Information
- 6.4.2 Pfizer Inc. Business Overview
- 6.4.3 Pfizer Inc. CGRP Monoclonal Antibodies Revenue, Global Share and Gross Margin (2020-2025)
- 6.4.4 Pfizer Inc. CGRP Monoclonal Antibodies Product Portfolio
- 6.4.5 Pfizer Inc. Recent Developments
- 6.5 Lilly Inc.
- 6.5.1 Lilly Inc. Comapny Information
- 6.5.2 Lilly Inc. Business Overview
- 6.5.3 Lilly Inc. CGRP Monoclonal Antibodies Revenue, Global Share and Gross Margin (2020-2025)
- 6.5.4 Lilly Inc. CGRP Monoclonal Antibodies Product Portfolio
- 6.5.5 Lilly Inc. Recent Developments
- 6.6 Lundbeck
- 6.6.1 Lundbeck Comapny Information
- 6.6.2 Lundbeck Business Overview
- 6.6.3 Lundbeck CGRP Monoclonal Antibodies Revenue, Global Share and Gross Margin (2020-2025)
- 6.6.4 Lundbeck CGRP Monoclonal Antibodies Product Portfolio
- 6.6.5 Lundbeck Recent Developments
- 6.7 Novartis International AG
- 6.7.1 Novartis International AG Comapny Information
- 6.7.2 Novartis International AG Business Overview
- 6.7.3 Novartis International AG CGRP Monoclonal Antibodies Revenue, Global Share and Gross Margin (2020-2025)
- 6.7.4 Novartis International AG CGRP Monoclonal Antibodies Product Portfolio
- 6.7.5 Novartis International AG Recent Developments
- 6.8 Teva
- 6.8.1 Teva Comapny Information
- 6.8.2 Teva Business Overview
- 6.8.3 Teva CGRP Monoclonal Antibodies Revenue, Global Share and Gross Margin (2020-2025)
- 6.8.4 Teva CGRP Monoclonal Antibodies Product Portfolio
- 6.8.5 Teva Recent Developments
- 7 North America
- 7.1 North America CGRP Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2 North America CGRP Monoclonal Antibodies Market Size by Country (2020-2025)
- 7.3 North America CGRP Monoclonal Antibodies Market Size Forecast by Country (2026-2031)
- 8 Europe
- 8.1 Europe CGRP Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2 Europe CGRP Monoclonal Antibodies Market Size by Country (2020-2025)
- 8.3 Europe CGRP Monoclonal Antibodies Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific
- 9.1 Asia-Pacific CGRP Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2 Asia-Pacific CGRP Monoclonal Antibodies Market Size by Country (2020-2025)
- 9.3 Asia-Pacific CGRP Monoclonal Antibodies Market Size Forecast by Country (2026-2031)
- 10 South America
- 10.1 South America CGRP Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2 South America CGRP Monoclonal Antibodies Market Size by Country (2020-2025)
- 10.3 South America CGRP Monoclonal Antibodies Market Size Forecast by Country (2026-2031)
- 11 Middle East & Africa
- 11.1 Middle East & Africa CGRP Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2 Middle East & Africa CGRP Monoclonal Antibodies Market Size by Country (2020-2025)
- 11.3 Middle East & Africa CGRP Monoclonal Antibodies Market Size Forecast by Country (2026-2031)
- 12 Concluding Insights
- 13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.